Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.

In paying $5.5bn for immediate rights to three Daiichi Sankyo assets Merck & Co has made its biggest bet on ADCs to date.

However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.

A study to back accelerated approval is to start next year, but the prospect of seeing a fully greenlit Padcev before then looms large.

One first-in-human study and two deals in a single day sees companies blaze the ADC trail.

Seagen/Genmab’s confirmatory cervical cancer trial is toplined positive, putting up a fresh roadblock for Iovance’s accelerated filing plans.